Product Image
Please see full prescribing and safety information, including boxed warning, for LEVOFLOXACIN premix bags. LEVOFLOXACIN Package Insert premixed bags and LEVOFLOXACIN Medication Guide premix bags

Available in:

  • 250 mg per 50 mL in 5% Dextrose premix bags
  • 500 mg per 100 mL in 5% Dextrose premix bags
  • 750 mg per 150 mL in 5% Dextrose premix bags

Benefits:

  • AP Rated
  • Preservative-free
  • DEHP-free
  • PVC-free
  • Not made with natural rubber latex

LEVOFLOXACIN Injection in 5% Dextrose

Brand Name Equivalent: LEVAQUIN® (LEVAQUIN is a registered trademark of Daiichi Sankyo Company.)
Therapeutic Category: Anti-Infective / Antibiotic

PreventIV MeasuresTM Features:

  • Easy-to-read drug name and strengths printed on the bags and front and back of overwraps
  • Bar codes on the overwraps for ease of scanning
  • Unique label design to help products stand out on the shelf
  • Enhanced packaging and labeling designed to promote safety and help reduce the risk of medication errors
  • Ready-to-use premix bags facilitate adherence to USP
NDC
#25021
Description Strength Fill
Volume
Concentration Container
Size
Closure Unit
of Sale
132-81 Premix Bag 250 mg 50 mL 5 mg per mL N/A N/A 24
132-82 Premix Bag 500 mg 100 mL 5 mg per mL N/A N/A 24
132-83 Premix Bag 750 mg 150 mL 5 mg per mL N/A N/A 24
WARNING Fluoroquinolones, including LEVOFLOXACIN INJECTION in 5% dextrose, are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants [See Warnings and Precautions (5.1)].
Fluoroquinolones, including LEVOFLOXACIN INJECTION in 5% dextrose, may exacerbate muscle weakness in persons with myasthenia gravis. Avoid LEVOFLOXACIN INJECTION in 5% dextrose in patients with a known history of myasthenia gravis [See Warnings and Precautions (5.2)]